Insulin analogs and cancer: A note of caution

Frontiers in Endocrinology

Volumn 5, Issue MAY, 2014, Pages

  Janssen, Joseph A M J L ^a   Varewijck, Aimee J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Hyperglycemia; IGF I receptor; Insulin; Insulin analogs; Insulin receptor A; Insulin receptor B

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR; METFORMIN; PROTEIN TYROSINE PHOSPHATASE SHP; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; CANCER GROWTH; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; GENE DUPLICATION; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SEQUENCE HOMOLOGY; UPREGULATION;

EID: 84905498813     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00079     Document Type: Review

References (51)

1. Colhoun HM, Group SE. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia (2009) 52:1755-65. doi:10.1007/s00125-009-1453-1
2. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 52:1766-77. doi:10.1007/s00125-009-1440-6
3. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia (2009) 52:1732-44. doi:10.1007/s00125-009-1418-4
4. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia (2009) 52:1745-54. doi:10.1007/s00125-009-1444-2
5. Chan SJ, Steiner DF. Insulin through the ages: phylogeny of a growth promoting and metabolic regulatory hormone. Am Zool (2000) 40:213-22. doi:10.1668/0003-1569(2000)040[0213:ITTAPO]2.0.CO;2
6. Humbel RE. Insulin-like growth factors I and II. Eur J Biochem (1990) 190:445-62. doi:10.1111/j.1432-1033.1990.tb15595.x
7. Hernandez-Sanchez C, Mansilla A, De Pablo F, Zardoya R. Evolution of the insulin receptor family and receptor isoform expression in vertebrates. Mol Biol Evol (2008) 25:1043-53. doi:10.1093/molbev/msn036
8. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer (2009) 16:1103-23. doi:10.1677/ERC-09-0087
9. Froesch ER, Zapf J. Insulin-like growth factors and insulin: comparative aspects. Diabetologia (1985) 28:485-93. doi:10.1007/BF00281982
10. King GL. Insulin receptors on vascular cells. In: Bruun NE, Smith U, Hedner T, Hokfelt B, editors. Novo Nordisk Foundation Symposium. Amsterdam: Elsevier Science Publishers BV (1991). p. 183-97.
11. Varewijck AJ, Janssen JA. Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer (2012) 19:F63-75. doi:10.1530/ERC-12-0026
12. Owens D, Barnett A. Designer insulins; have they revolutionized insulin therapy? Chapter 14. In: Betteridge DJ, editor. Diabetes, Current Perspectives. London: Martin Dunitz Ltd (2000). p. 223-66.
13. Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol (2010) 47:271-8. doi:10.1007/s00592-010-0215-3
14. Stammberger I, Seipke G, Bartels T. Insulin glulisine - a comprehensive preclinical evaluation. Int J Toxicol (2006) 25:25-33. doi:10.1080/10915810500488379
15. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 49:999-1005. doi:10.2337/diabetes.49.6.999
16. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia (2010) 53:1743-53. doi:10.1007/s00125-010-1760-6
17. Nasrallah SN, Reynolds LR. Insulin degludec, the new generation basal insulin or just another basal insulin? Clin Med Insights Endocrinol Diabetes (2012) 5:31-7. doi:10.4137/CMED.S9494
18. Monnier L, Colette C, Owens D. Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend? Diabetes Metab (2013) 39:468-76. doi:10.1016/j.diabet.2013.09.003
19. Chen JW, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab (2003) 284:E1149-55. doi:10.1152/ajpendo.00410.2002
20. Janssen JA. Insulin-like growth factor I: pros and cons of a bioassay. Horm Res Paediatr (2011) 76(Suppl 1):106-10. doi:10.1159/000329191
21. Varewijck AJ, Goudzwaard JA, Brugts MP, Lamberts SW, Hofland LJ, Janssen JA. Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. Growth Horm IGF Res (2010) 20:427-31. doi:10.1016/j.ghir.2010.10.002
22. Varewijck AJ, Janssen JA, Vahatalo M, Hofland LJ, Lamberts SW, Yki-Jarvinen H. Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia (2012) 55:1186-94. doi:10.1007/s00125-011-2435-7
23. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia (2006) 49:442-51. doi:10.1007/s00125-005-0132-0
24. Bailey CJ, Turner RC. Metformin. N Engl J Med (1996) 334:574-9. doi:10.1056/NEJM199602293340906
25. Arafat AM, Weickert MO, Frystyk J, Spranger J, Schofl C, Mohlig M, et al. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab (2009) 94:5093-101. doi:10.1210/jc.2009-0875
26. Brugts MP, Van Duijn CM, Hofland LJ, Witteman JC, Lamberts SW, Janssen JA. IGF-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome. Diabetes (2010) 59:505-8. doi:10.2337/db09-0583
27. Vitale G, Brugts MP, Ogliari G, Castaldi D, Fatti LM, Varewijck AJ, et al. Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring. Aging (Albany NY) (2012) 4:580-9.
28. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R, et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One (2010) 5:e9540. doi:10.1371/journal.pone.0009540
29. Varewijck AJ, Yki-Jarvinen H, Schmidt R, Tennagels N, Janssen JA. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes (2013) 62:2539-44. doi:10.2337/db12-1773
30. Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 367:319-28. doi:10.1056/NEJMoa1203858
31. Garcia-Jimenez C, Garcia-Martinez JM, Chocarro-Calvo A, De La Vieja A. A new link between diabetes and cancer: enhanced WNT/beta-catenin signaling by high glucose. J Mol Endocrinol (2014) 52:R51-66. doi:10.1530/JME-13-0152
32. Clemmons D, Maile L, Xi G, Shen X, Radhakrishnan Y. IGF-I signaling in response to hyperglycemia and the development of diabetic complications. Curr Diabetes Rev (2011) 7:235-45. doi:10.2174/157339911796397848
33. Buysschaert M, Sadikot S. Diabetes and cancer: a 2013 synopsis. Diabetes Metab Syndr (2013) 7:247-50. doi:10.1016/j.dsx.2013.08.001
34. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev (2004) 13:915-9.
35. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care (2007) 30:561-7. doi:10.2337/dc06-0922
36. Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, Selmer R, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med (2009) 6:e1000201. doi:10.1371/journal.pmed.1000201
37. Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes (2010) 59:1254-60. doi:10.2337/db09-1371
38. Emerging Risk Factors Collaboration; Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med (2011) 364:829-41. doi:10.1056/NEJMoa1008862
39. Girnita L, Worrall C, Takahashi SI, Seregard S, Girnita A. Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci (2013). doi:10.1007/s00018-013-1514-y
40. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J (1996) 315(Pt 1):271-9.
41. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J (1990) 9:2409-13.
42. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 30:586-623. doi:10.1210/er.2008-0047
43. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 19:3278-88.
44. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer (2011) 18:R125-47. doi:10.1530/ERC-11-0074
45. Denley A, Bonython ER, Booker GW, Cosgrove LJ, Forbes BE, Ward CW, et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol (2004) 18:2502-12. doi:10.1210/me.2004-0183
46. Varewijck AJ, Brugts MP, Frystyk J, Goudzwaard JA, Uitterlinden P, Waaijers AM, et al. Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling. Mol Cell Endocrinol (2013) 365:17-24. doi:10.1016/j.mce.2012.08.021
47. Boucher J, Tseng YH, Kahn CR. Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J Biol Chem (2010) 285:17235-45. doi:10.1074/jbc.M110.118620
48. Versteyhe S, Klaproth B, Borup R, Palsgaard J, Jensen M, Gray SG, et al. IGF-I, IGF-II, and insulin stimulate different gene expression responses through binding to the IGF-I receptor. Front Endocrinol (Lausanne) (2013) 4:98. doi:10.3389/fendo.2013.00098
49. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med (2007) 24:1412-8. doi:10.1111/j.1464-5491.2007.02279.x
50. Braga M, Casanova A, Teoh H, Dawson KC, Gerstein HC, Fitchett DH, et al. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiol (2010) 26:297-302. doi:10.1016/S0828-282X(10)70393-7
51. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2009) 32:193-203. doi:10.2337/dc08-9025